We are live on ! Find out more
BC

Birchview Capital Portfolio holdings

AUM $176M
1-Year Est. Return 95.04%
This Fund
S&P 500
This Quarter Est. Return
-7.78%
1 Year Est. Return
+95.04%
3 Year Est. Return
+233.14%
5 Year Est. Return
+280.2%
10 Year Est. Return
+1,023.63%
AUM
$147M
AUM Growth
-$20.2M
Cap. Flow
+$2M
Cap. Flow %
1.36%
Top 10 Hldgs %
70.43%
Holding
67
New
5
Increased
11
Reduced
3
Closed
3

Top Buys

Rank Stock Value
1
PTGX icon
Protagonist Therapeutics
PTGX
+$1.19M
2
PRTA icon
Prothena Corp
PRTA
+$621K
3
CYTK icon
Cytokinetics
CYTK
+$442K
4
GOSS icon
Gossamer Bio
GOSS
+$368K
5
AVEO
AVEO Pharmaceuticals, Inc.
AVEO
+$239K

Top Sells

Rank Stock Value
1
XLRN
Acceleron Pharma
XLRN
+$1.05M
2
TBIO
Translate Bio, Inc. Common Stock
TBIO
+$826K
3
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$373K
4
HOOK
HOOKIPA Pharma
HOOK
+$183K
5
CCXI
ChemoCentryx, Inc.
CCXI
+$77.9K

Sector Composition

Rank Sector Weight
1 Healthcare 96.08%
2 Energy 2.11%
3 Consumer Staples 0.26%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OVV icon
26
Ovintiv
OVV
$16.2B
$1.12M 0.76%
34,200
– –
IMGN
27
DELISTED
Immunogen Inc
IMGN
$1.08M 0.73%
190,000
– –
CGEM icon
28
Cullinan Oncology
CGEM
$1.08B
$1.02M 0.69%
45,114
– –
CORT icon
29
Corcept Therapeutics
CORT
$9.83B
$984K 0.67%
50,000
– –
CYTK icon
30
Cytokinetics
CYTK
$10.7B
$894K 0.61%
25,000
+15,000
+150% +$442K
PGNY icon
31
Progyny
PGNY
$2.49B
$840K 0.57%
15,000
– –
SLNO
32
DELISTED
Soleno Therapeutics
SLNO
$811K 0.55%
58,460
– –
CFRX
33
DELISTED
ContraFect Corporation
CFRX
$810K 0.55%
2,500
– –
KALV
34
DELISTED
KalVista Pharmaceuticals
KALV
$698K 0.48%
40,000
– –
PTGX icon
35
Protagonist Therapeutics
PTGX
$8.64B
$673K 0.46%
38,000
+28,000
+280% +$1.19M
PXD
36
DELISTED
Pioneer Natural Resource Co.
PXD
$633K 0.43%
3,800
– –
NARI
37
DELISTED
Inari Medical, Inc. Common Stock
NARI
$568K 0.39%
7,000
– –
GTHX
38
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$537K 0.37%
40,000
– –
ZNTL icon
39
Zentalis Pharmaceuticals
ZNTL
$357M
$533K 0.36%
8,000
– –
ELTX icon
40
Elicio Therapeutics
ELTX
$79.8M
$531K 0.36%
5,439
-623
-10% -$67.3K
TPTX
41
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$531K 0.36%
8,000
– –
GOSS icon
42
Gossamer Bio
GOSS
$68.9M
$503K 0.34%
+40,000
New +$368K
TGTX icon
43
TG Therapeutics
TGTX
$8.26B
$499K 0.34%
15,000
– –
CCXI
44
DELISTED
ChemoCentryx, Inc.
CCXI
$428K 0.29%
25,000
-5,000
-17% -$77.9K
BIOR
45
DELISTED
Biora Therapeutics, Inc. Common Stock
BIOR
$410K 0.28%
1,080
– –
XNCR icon
46
Xencor
XNCR
$1.39B
$402K 0.27%
12,300
– –
APLS
47
DELISTED
Apellis Pharmaceuticals
APLS
$396K 0.27%
12,000
+4,000
+50% +$225K
STOK icon
48
Stoke Therapeutics
STOK
$1.72B
$382K 0.26%
15,000
– –
FOLD
49
DELISTED
Amicus Therapeutics
FOLD
$363K 0.25%
38,000
– –
ELUT icon
50
Elutia
ELUT
$41.1M
$348K 0.24%
50,000
+20,000
+67% +$163K
1
2
3

Similar funds

RWA
Resolute Wealth Advisor Findlay, Ohio $176M AUM
BAM
Boyar Asset Management New York $176M AUM 20.04% 1-Year Est. Return
TIM
Tevis Investment Management Plano, Texas $176M AUM 18.14% 1-Year Est. Return
TFCM
Taylor Frigon Capital Management Scottsdale, Arizona $176M AUM 24.25% 1-Year Est. Return
FPW
Flywheel Private Wealth Los Altos, California $176M AUM 26.12% 1-Year Est. Return
LWM
Lifetime Wealth Management Rockwall, Texas $176M AUM
PFA
Providence Financial Advisors Overland Park, Kansas $175M AUM
DAM
Draper Asset Management Smithtown, New York $176M AUM 37.45% 1-Year Est. Return

Birchview Capital's Q3 2021 Portfolio in Review

As of Q3 2021, Birchview Capital held 67 positions worth $147M, down 12% from $167M the previous quarter. Its ten largest holdings account for 70% of the portfolio.

Birchview Capital's Q3 2021 filing shows 5 new, 11 increased, 3 reduced and 3 closed positions. Its largest new stake was Gossamer Bio: 40,000 shares worth $503K. The largest sale was Acceleron Pharma, an estimated $1.05M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 97% a quarter earlier, followed by Energy and Consumer Staples.

  • Birchview Capital's largest Q3 2021 buy was Gossamer Bio: 40,000 shares worth $503K.
  • Birchview Capital added most to Protagonist Therapeutics in Q3 2021, an estimated $1.19M increase.
  • Birchview Capital's biggest Q3 2021 reduction was Acceleron Pharma, cutting an estimated $1.05M.
  • Birchview Capital fully exited Translate Bio, Inc. Common Stock in Q3 2021, selling an estimated $826K.
  • Birchview Capital's ten largest holdings make up 70% of its $147M portfolio in Q3 2021.
  • Birchview Capital opened 5 new positions and closed 3 in Q3 2021.
  • Birchview Capital's portfolio value fell 12% quarter-over-quarter to $147M.

Based on Birchview Capital's 13F filing for Q3 2021, filed 12 Nov 2021.